Loss-making Vaccine Creator Luzhu Aims for IPO Booster Shot
The IPO-bound biotech is still developing its shingles vaccines and other antibody therapies, but the company has spent heavily in recent years on financial productsKey Takeaways:Losses of 1.26 billion yuan…
Recent Articles
RELATED ARTICLES
- Health Guard plans dual listing to fund HPV vaccine fight
-
With healthier finances, Clover Bio shifts to flu and RSV vaccines
2197.HK
-
Fosun Pharma, CanSino take different paths as Covid lift fade
2196.HK 6185.HK
- China’s mRNA pioneer Stemirna faces post-Covid reinvention test
- Funding boost gets Sunho Biologics over the IPO filing line
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
Discover hidden China stock gems in our weekly newsletter